Small Molecule Drugs Are Coming for HCV
Hepatitis C: small molecules, big business
Although interferons and ribavirin currently dominate the hepatitis C treatments market and soon-to-be-launched products will predominantly be improvements to these types of drugs, small molecule antivirals are expected to gain a much greater footing in the long-term. Indeed, the launches of the first two hepatitis C virus (HCV)-specific small molecule antiviral drugs, expected in 2011 and 2012, are predicted to be instrumental in helping to grow the value of the HCV pharmaceutical market in the next decade.
Source: Datamonitor Researchwire